1.
原发性扩张型心肌病患者临床资料比较结果
Comparison of clinical data in idiopathic DCM
| Items | LVRR (n=43) | NON-LVRR(n=209) | P |
| a: Mean ± Standard deviation, b: Number/%, *: The original value is transformed by logarithm. LVRR: left ventricular reverse remodeling, BMI: Body Mass Index, NT-proBNP: N-teminal probrain natriuretic peptide, RDW: Red cell distribution width, LVEDD: End-diastolic diameter, LVEF: Left ventricular ejection fration, ACEI: Angiotensin converting enzyme inhibitor, ARB: Angiotensin Ⅱ recptor antagonist. | |||
| Agea (years) | 40.21±11.24 | 41.45±9.86 | 0.703 |
| Male [case/(%)] | 32/(74.42) | 161/(77.03) | 0.379 |
| BMIa (kg/m2） | 23.43±2.89 | 23.84±3.00 | 0.410 |
| Smokeb | 5 | 23 | 0.906 |
| Heavy drinkingb | 2 | 5 | 0.412 |
| NYHA classification | |||
| Ⅰb | 4 | 15 | 0.631 |
| Ⅱb | 11 | 54 | 0.959 |
| Ⅲb | 17 | 85 | 0.890 |
| Ⅳb | 11 | 55 | 0.921 |
| Heart failure coursea (month) | 16.74±12.25 | 25.25±20.43 | 0.009 |
| Hypertensionb | 4 | 16 | 0.716 |
| Diabetesb | 3 | 14 | 0.947 |
| Ventricular Tachyarrhythmiasb | 2 | 5 | 0.412 |
| Baseline data | |||
| Systolic blood pressurea (mmHg) | 124.32±17.44 | 116.99±16.58 | 0.009 |
| Non electrolyte disbalanceb | 25 | 68 | 0.002 |
| RDWa (%) | 13.75±0.88 | 14.31±0.87 | < 0.001 |
| Hemoglobina (g/L) | 137.21±10.88 | 135.52±12.97 | 0.427 |
| Plateleta (109/L) | 210.26±45.45 | 219.67±51.00 | 0.262 |
| Albumina (g/L) | 36.01±3.05 | 35.78±3.20 | 0.668 |
| Uric Acida (mmol/L) | 397.51±85.88 | 417.66±84.11 | 0.155 |
| Creatininea (μmol/L) | 89.60±25.45 | 97.10±43.31 | 0.275 |
| Glomerular filtration ratea (%) | 85.23±14.02 | 84.24±12.88 | 0.649 |
| Cholesterola (mmol/L) | 3.45±0.77 | 3.56±0.99 | 0.482 |
| Triglyceridea (mmol/L) | 1.23±0.44 | 1.33±0.52 | 0.249 |
| Low density lipoproteina (mmol/L) | 2.51±0.68 | 2.70±0.94 | 0.217 |
| NT-proBNPa* (pg/mL) | 3.19±0.66 | 3.38±0.46 | 0.019 |
| Troponin Ia (ng/mL) | 0.024±0.02 | 0.031±0.04 | 0.176 |
| LVEDDa (mm) | 63.22±6.01 | 65.57±5.13 | 0.009 |
| LVEFa (%) | 33.80±10.37 | 28.88±7.25 | < 0.001 |
| Discharge medication (Number/%) | |||
| ACE/ARBb | 40/(93.02) | 165/(78.94) | 0.031 |
| β-Blokerb | 41/(95.34) | 155/(74.16) | 0.014 |
| Spirolactoneb | 41/(95.34) | 182/(87.08) | 0.454 |
| Information during Follow-up | |||
| LVEDDa (mm) | 46.18±5.90 | 61.12±5.57 | < 0.001 |
| LVEFa (%) | 50.41±9.88 | 36.57±7.43 | < 0.001 |
| Mean exercise tolerance (MET)a | 6.24±0.86 | 3.62±0.81 | < 0.001 |